Cyclobenzaprine HCl

×

Overview

What is Cyclobenzaprine HCl?

Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine salt with the empirical formula CHN•HCl and a molecular weight of 311.9. It has a melting point of 217°C, and a pKa of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-(-dibenzo[] cyclohepten-5-ylidene)-N, N-dimethyl-1-propanamine hydrochloride, and has the following structural formula:

Cyclobenzaprine HCl is supplied as 5 and 10 mg tablets for oral administration.

Cyclobenzaprine HCl tablets, USP 5 mg contain the following inactive ingredients: carnauba wax powder, croscarmellose sodium, FD&C Yellow #6 Aluminum Lake, iron oxide yellow, lactose monohydrate, lecithin, macrogol, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, silicon dioxide, talc, titanium dioxide.

Cyclobenzaprine HCl tablets, USP 10 mg contain the following inactive ingredients: carnauba wax powder, croscarmellose sodium, D&C Yellow #10 Aluminum Lake, FD&C Yellow #6 Aluminum Lake, hypromellose, iron oxide yellow, lactose monohydrate, macrogol, magnesium stearate, methylparaben, microcrystalline cellulose, polysorbate, potassium sorbate, propylparaben, propylene glycol, silicon dioxide, sodium citrate, titanium dioxide, xanthan gum.

What does Cyclobenzaprine HCl look like?

What are the available doses of Cyclobenzaprine HCl?

Sorry No records found.

What should I talk to my health care provider before I take Cyclobenzaprine HCl?

Sorry No records found

How should I use Cyclobenzaprine HCl?

Cyclobenzaprine HCl tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.

Cyclobenzaprine HCl tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.

Cyclobenzaprine HCl tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.

For most patients, the recommended dose of cyclobenzaprine HCl tablet is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Use of cyclobenzaprine HCl for periods longer than two or three weeks is not recommended. (see ).

Less frequent dosing should be considered for hepatically impaired or elderly patients (see , and ).

What interacts with Cyclobenzaprine HCl?

Hypersensitivity to any component of this product.

Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.

Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

Hyperthyroidism.

What are the warnings of Cyclobenzaprine HCl?

Serotonin Syndrome

Cyclobenzaprine is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see , below, and ).

Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke.

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.

What are the precautions of Cyclobenzaprine HCl?

General

Because of its atropine-like action, cyclobenzaprine HCl should be used with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication.

Impaired Hepatic Function

The plasma concentration of cyclobenzaprine is increased in patients with hepatic impairment (see ). These patients are generally more susceptible to drugs with potentially sedating effects, including cyclobenzaprine. Cyclobenzaprine HCl should be used with caution in subjects with mild hepatic impairment starting with a 5 mg dose and titrating slowly upward. Due to the lack of data in subjects with more severe hepatic insufficiency, the use of cyclobenzaprine HCl in subjects with moderate to severe impairment is not recommended.

Information for Patients

Cyclobenzaprine HCl, especially when used with alcohol or other CNS depressants, may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. In the elderly, the frequency and severity of adverse events associated with the use of cyclobenzaprine, with or without concomitant medications, is increased. In elderly patients, cyclobenzaprine HCl should be initiated with a 5 mg dose and titrated slowly upward.

Patients should be cautioned about the risk of serotonin syndrome with the concomitant use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Patients should be advised of the signs and symptoms of serotonin syndrome, and be instructed to seek medical care immediately if they experience these symptoms (see , and see ).

Drug Interactions

Cyclobenzaprine HCl may have life-threatening interactions with MAO inhibitors. (See .) Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see )

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.

Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In rats treated with cyclobenzaprine HCl for up to 67 weeks at doses of approximately 5 to 40 times the maximum recommended human dose, pale, sometimes enlarged, livers were noted and there was a dose-related hepatocyte vacuolation with lipidosis. In the higher dose groups this microscopic change was seen after 26 weeks and even earlier in rats which died prior to 26 weeks; at lower doses, the change was not seen until after 26 weeks.

Cyclobenzaprine did not affect the onset, incidence or distribution of neoplasia in an 81-week study in the mouse or in a 105-week study in the rat.

At oral doses of up to 10 times the human dose, cyclobenzaprine did not adversely affect the reproductive performance or fertility of male or female rats. Cyclobenzaprine did not demonstrate mutagenic activity in the male mouse at dose levels of up to 20 times the human dose.

Pregnancy

Pregnancy Category B: Reproduction studies have been performed in rats, mice and rabbits at doses up to 20 times the human dose, and have revealed no evidence of impaired fertility or harm to the fetus due to cyclobenzaprine HCl. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because cyclobenzaprine is closely related to the tricyclic antidepressants, some of which are known to be excreted in human milk, caution should be exercised when cyclobenzaprine HCl is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of cyclobenzaprine HCl in pediatric patients below 15 years of age have not been established.

Use in the Elderly

The plasma concentration of cyclobenzaprine is increased in the elderly (see ). The elderly may also be more at risk for CNS adverse events such as hallucinations and confusion, cardiac events resulting in falls or other sequelae, drug-drug and drug-disease interactions. For these reasons, in the elderly, cyclobenzaprine should be used only if clearly needed. In such patients cyclobenzaprine HCl should be initiated with a 5 mg dose and titrated slowly upward.

Array

What are the side effects of Cyclobenzaprine HCl?

Incidence of most common adverse reactions in the 2 double-blind, placebo-controlled 5 mg studies (incidence of >3% on cyclobenzaprine HCl tablets, USP 5 mg):

Adverse reactions which were reported in 1% to 3% of the patients were: abdominal pain, acid regurgitation, constipation, diarrhea, dizziness, nausea, irritability, mental acuity decreased, nervousness, upper respiratory infection, and pharyngitis.

The following list of adverse reactions is based on the experience in 473 patients treated with cyclobenzaprine HCl tablets, USP 10 mg in additional controlled clinical studies, 7,607 patients in the post-marketing surveillance program, and reports received since the drug was marketed. The overall incidence of adverse reactions among patients in the surveillance program was less than the incidence in the controlled clinical studies.

The adverse reactions reported most frequently with cyclobenzaprine HCl were drowsiness, dry mouth and dizziness. The incidence of these common adverse reactions was lower in the surveillance program than in the controlled clinical studies:

Among the less frequent adverse reactions, there was no appreciable difference in incidence in controlled clinical studies or in the surveillance program. Adverse reactions which were reported in 1% to 3% of the patients were: fatigue/tiredness, asthenia, nausea, constipation, dyspepsia, unpleasant taste, blurred vision, headache, nervousness, and confusion.

The following adverse reactions have been reported in post-marketing experience or with an incidence of less than 1% of patients in clinical trials with the 10 mg tablet:

Body as a Whole

Cardiovascular

Digestive

Hypersensitivity

Musculoskeletal

Nervous System and Psychiatric

Skin

Special Senses

Urogenital

	Cyclobenzaprine HCl Tablets, USP 5 mgN=464	Cyclobenzaprine HClTablets, USP 10 mgN=249
Drowsiness	29%	38%	10%
Dry Mouth	21%	32%	7%
Fatigue	6%	6%	3%
Headache	5%	5%	8%
	Clinical Studies With Cyclobenzaprine HCl Tablets, USP 10 mg	Surveillance Program With Cyclobenzaprine HCl Tablets, USP 10 mg
Drowsiness	39%	16%
Dry Mouth	27%	7%
Dizziness	11%	3%

Causal Relationship Unknown

           : Chest pain; edema.

           : Hypertension; myocardial infarction; heart block; stroke.

           : Paralytic ileus, tongue discoloration; stomatitis; parotid swelling.

           : Inappropriate ADH syndrome.

           : Purpura; bone marrow depression; leukopenia; eosinophilia; thrombocytopenia.

           : Elevation and lowering of blood sugar levels; weight gain or loss.

           : Myalgia.

           : Decreased or increased libido; abnormal gait; delusions;            aggressive behavior; paranoia; peripheral neuropathy; Bell's palsy; alteration in EEG patterns;            extrapyramidal symptoms.

           : Dyspnea.

           : Photosensitization; alopecia.

           Impaired urination; dilatation of urinary tract; impotence; testicular swelling;            gynecomastia; breast enlargement; galactorrhea.

What should I look out for while using Cyclobenzaprine HCl?

Hypersensitivity to any component of this product.

Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.

Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

Hyperthyroidism.

Serotonin Syndrome

Cyclobenzaprine is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see , below, and ).

Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke.

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.

What might happen if I take too much Cyclobenzaprine HCl?

Although rare, deaths may occur from overdosage with cyclobenzaprine HCl tablets. Multiple drug ingestion (including alcohol) is common in deliberate cyclobenzaprine overdose. Signs and symptoms of toxicity may develop rapidly after cyclobenzaprine overdose; therefore, hospital monitoring is required as soon as possible. The acute oral LD50 of cyclobenzaprine HCl is approximately 338 and 425 mg/kg in mice and rats, respectively.

How should I store and handle Cyclobenzaprine HCl?

Store at 25°C (77° F); excursions permitted to 15-30 °C (59-86°F) [see USP Controlled Room Temperature].Cyclobenzaprine HCl tablets, USP 5 mg are orange-colored, film- coated, round biconvex tablets, debossed “148 O” on one side. Available in bottles of 100’s (NDC 69584-148-10) and 1000’s (NDC 69584-148-90). Cyclobenzaprine HCl tablets, USP 10 mg are yellow-colored, film- coated, round biconvex tablets, debossed “149 O” on one side. Available in bottles of 100’s (NDC 69584-149-10) and 1000’s (NDC 69584-149-90). Store at controlled room temperature, 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Rx Only For more information call 844‑508‑1455, 8:00 am - 6:00 pm CT, Monday – Friday MANUFACTURED BY: Oxford Pharmaceuticals LLC 301 Leaf lake Parkway Birmingham, AL 35211 8200003 Rev. 0118-00 Cyclobenzaprine HCl tablets, USP 5 mg are orange-colored, film- coated, round biconvex tablets, debossed “148 O” on one side. Available in bottles of 100’s (NDC 69584-148-10) and 1000’s (NDC 69584-148-90). Cyclobenzaprine HCl tablets, USP 10 mg are yellow-colored, film- coated, round biconvex tablets, debossed “149 O” on one side. Available in bottles of 100’s (NDC 69584-149-10) and 1000’s (NDC 69584-149-90). Store at controlled room temperature, 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Rx Only For more information call 844‑508‑1455, 8:00 am - 6:00 pm CT, Monday – Friday MANUFACTURED BY: Oxford Pharmaceuticals LLC 301 Leaf lake Parkway Birmingham, AL 35211 8200003 Rev. 0118-00 Cyclobenzaprine HCl tablets, USP 5 mg are orange-colored, film- coated, round biconvex tablets, debossed “148 O” on one side. Available in bottles of 100’s (NDC 69584-148-10) and 1000’s (NDC 69584-148-90). Cyclobenzaprine HCl tablets, USP 10 mg are yellow-colored, film- coated, round biconvex tablets, debossed “149 O” on one side. Available in bottles of 100’s (NDC 69584-149-10) and 1000’s (NDC 69584-149-90). Store at controlled room temperature, 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Rx Only For more information call 844‑508‑1455, 8:00 am - 6:00 pm CT, Monday – Friday MANUFACTURED BY: Oxford Pharmaceuticals LLC 301 Leaf lake Parkway Birmingham, AL 35211 8200003 Rev. 0118-00 Cyclobenzaprine HCl tablets, USP 5 mg are orange-colored, film- coated, round biconvex tablets, debossed “148 O” on one side. Available in bottles of 100’s (NDC 69584-148-10) and 1000’s (NDC 69584-148-90). Cyclobenzaprine HCl tablets, USP 10 mg are yellow-colored, film- coated, round biconvex tablets, debossed “149 O” on one side. Available in bottles of 100’s (NDC 69584-149-10) and 1000’s (NDC 69584-149-90). Store at controlled room temperature, 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Rx Only For more information call 844‑508‑1455, 8:00 am - 6:00 pm CT, Monday – Friday MANUFACTURED BY: Oxford Pharmaceuticals LLC 301 Leaf lake Parkway Birmingham, AL 35211 8200003 Rev. 0118-00 Cyclobenzaprine HCl tablets, USP 5 mg are orange-colored, film- coated, round biconvex tablets, debossed “148 O” on one side. Available in bottles of 100’s (NDC 69584-148-10) and 1000’s (NDC 69584-148-90). Cyclobenzaprine HCl tablets, USP 10 mg are yellow-colored, film- coated, round biconvex tablets, debossed “149 O” on one side. Available in bottles of 100’s (NDC 69584-149-10) and 1000’s (NDC 69584-149-90). Store at controlled room temperature, 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Rx Only For more information call 844‑508‑1455, 8:00 am - 6:00 pm CT, Monday – Friday MANUFACTURED BY: Oxford Pharmaceuticals LLC 301 Leaf lake Parkway Birmingham, AL 35211 8200003 Rev. 0118-00 Cyclobenzaprine HCl tablets, USP 5 mg are orange-colored, film- coated, round biconvex tablets, debossed “148 O” on one side. Available in bottles of 100’s (NDC 69584-148-10) and 1000’s (NDC 69584-148-90). Cyclobenzaprine HCl tablets, USP 10 mg are yellow-colored, film- coated, round biconvex tablets, debossed “149 O” on one side. Available in bottles of 100’s (NDC 69584-149-10) and 1000’s (NDC 69584-149-90). Store at controlled room temperature, 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Rx Only For more information call 844‑508‑1455, 8:00 am - 6:00 pm CT, Monday – Friday MANUFACTURED BY: Oxford Pharmaceuticals LLC 301 Leaf lake Parkway Birmingham, AL 35211 8200003 Rev. 0118-00 Cyclobenzaprine HCl tablets, USP 5 mg are orange-colored, film- coated, round biconvex tablets, debossed “148 O” on one side. Available in bottles of 100’s (NDC 69584-148-10) and 1000’s (NDC 69584-148-90). Cyclobenzaprine HCl tablets, USP 10 mg are yellow-colored, film- coated, round biconvex tablets, debossed “149 O” on one side. Available in bottles of 100’s (NDC 69584-149-10) and 1000’s (NDC 69584-149-90). Store at controlled room temperature, 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Rx Only For more information call 844‑508‑1455, 8:00 am - 6:00 pm CT, Monday – Friday MANUFACTURED BY: Oxford Pharmaceuticals LLC 301 Leaf lake Parkway Birmingham, AL 35211 8200003 Rev. 0118-00

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Estimates of mean oral bioavailability of cyclobenzaprine range from 33% to 55%. Cyclobenzaprine exhibits linear pharmacokinetics over the dose range 2.5 mg to 10 mg, and is subject to enterohepatic circulation. It is highly bound to plasma proteins. Drug accumulates when dosed three times a day, reaching steady-state within 3 to 4 days at plasma concentrations about four-fold higher than after a single dose. At steady state in healthy subjects receiving 10 mg t.i.d. (n=18), peak plasma concentration was 25.9 ng/mL (range, 12.8 to 46.1 ng/mL), and area under the concentration-time (AUC) curve over an 8-hour dosing interval was 177 ng.hr/mL (range, 80 to 319 ng.hr/mL).

Cyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney. Cytochromes P-450, 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine is eliminated quite slowly, with an effective half-life of 18 hours (range 8 to 37 hours; n=18); plasma clearance is 0.7 L/min.

The plasma concentration of cyclobenzaprine is generally higher in the elderly and in patients with hepatic impairment.

(See and .)

Non-Clinical Toxicology

Hypersensitivity to any component of this product.

Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.

Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

Hyperthyroidism.

Serotonin Syndrome

Cyclobenzaprine is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see , below, and ).

Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke.

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.

Cyclobenzaprine HCl may have life-threatening interactions with MAO inhibitors. (See .) Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see )

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.

Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.

Because of its atropine-like action, cyclobenzaprine HCl should be used with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication.

Incidence of most common adverse reactions in the 2 double-blind, placebo-controlled 5 mg studies (incidence of >3% on cyclobenzaprine HCl tablets, USP 5 mg):

Adverse reactions which were reported in 1% to 3% of the patients were: abdominal pain, acid regurgitation, constipation, diarrhea, dizziness, nausea, irritability, mental acuity decreased, nervousness, upper respiratory infection, and pharyngitis.

The following list of adverse reactions is based on the experience in 473 patients treated with cyclobenzaprine HCl tablets, USP 10 mg in additional controlled clinical studies, 7,607 patients in the post-marketing surveillance program, and reports received since the drug was marketed. The overall incidence of adverse reactions among patients in the surveillance program was less than the incidence in the controlled clinical studies.

The adverse reactions reported most frequently with cyclobenzaprine HCl were drowsiness, dry mouth and dizziness. The incidence of these common adverse reactions was lower in the surveillance program than in the controlled clinical studies:

Among the less frequent adverse reactions, there was no appreciable difference in incidence in controlled clinical studies or in the surveillance program. Adverse reactions which were reported in 1% to 3% of the patients were: fatigue/tiredness, asthenia, nausea, constipation, dyspepsia, unpleasant taste, blurred vision, headache, nervousness, and confusion.

The following adverse reactions have been reported in post-marketing experience or with an incidence of less than 1% of patients in clinical trials with the 10 mg tablet:

Body as a Whole

Cardiovascular

Digestive

Hypersensitivity

Musculoskeletal

Nervous System and Psychiatric

Skin

Special Senses

Urogenital

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: